Puma Biotech (PBYI) Stock up as Q2 Earnings & Sales Beat
Jobs with Puma Biotechnology
Puma Biotech plunges on drug side effects
Puma Biotechnology
Puma Biotechnology
Puma Biotechnology
Puma Biotech Strikes Deal to Develop and Market its Breast Cancer Drug in China - Los Angeles Business Journal
Puma Biotech (PBYI) Stock up as Q2 Earnings & Sales Beat
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | citybiz
Puma Biotech Stock Struggles To Find Its Footing In Crowded Oncology Space (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | Business Wire
Puma Biotechnology Announces $10 Million Private Placement | Business Wire
Puma Biotechnology - Crunchbase Company Profile & Funding
Is Puma off the cancer M&A list? With Nerlyx marketing deal, some investors think so | Fierce Pharma
Puma Biotech (PBYI) Inks Agreement for Takeda's Alisertib
Puma Biotechnology and Bixink Therapeutics Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in South Korea | Business Wire
SEC charges former Puma biotech exec with $1.1 million in insider trading
Exhibitor Puma Biotechnology 02-20 - Scripps CME Connection
PUMA BIOTECHNOLOGY, INC. FORM 10-K - Biotech Due Diligence
Puma Biotech Gets $100M Loan to Boost Breast Cancer Drug - Los Angeles Business Journal
Former Puma Biotech executive gets U.S. prison term for insider trading | Reuters.com
Puma Biotechnology Reports Results of Neratinib (PB272) in P-III NALA Trial for 3L HER2-Positive Metastatic Breast Cancer
Puma Biotech (PBYI) Inks Agreement for Takeda's Alisertib
Puma Biotechnology, Inc. | LinkedIn
Puma Biotechnology
Puma Biotech Plunges on Sharp Drop in Cancer-Drug Sales - TheStreet
